How Do Oncolytic Viruses Target Cancer Cells?

Oncolytic viruses selectively infect and destroy malignant cells while sparing healthy tissue by exploiting fundamental biological differences between tumors and normal cells. Malignant transformation frequently involves defective antiviral signaling pathways, overexpression of specific surface receptors, altered cellular metabolism, and impaired apoptotic machinery. These molecular aberrations create an ideal environment for viral entry, replication, and cell lysis, transforming naturally occurring or engineered viruses into targeted antitumor agents.

Aberrant Antiviral Defenses

Healthy cells rely on robust innate immune pathways to detect and neutralize viral infections. Upon viral entry, pattern recognition receptors trigger signaling cascades that produce type I interferons (IFN-α and IFN-β). This activates the JAK-STAT pathway, resulting in the upregulation of hundreds of interferon-stimulated genes (ISGs). Among these, protein kinase R (PKR) and 2'-5'-oligoadenylate synthetase (OAS) act to halt protein synthesis and degrade viral RNA, arresting the infection.

In contrast, tumor cells frequently downregulate or mutate components of the type I interferon pathway to evade immune surveillance and facilitate unrestricted proliferation. Deficiencies in receptors, interferon regulatory factors (such as IRF3 and IRF7), or downstream kinases permit oncolytic viruses to replicate unchecked. Without functional antiviral defenses, cancer cells cannot prevent the assembly of viral progeny, culminating in cell death.

Receptor Overexpression on Tumor Surfaces

Viral tropism depends heavily on the presence of specific cell-surface receptors required for binding and internalisation. Many receptors exploited by viruses are overexpressed on malignant cells to support cell adhesion, migration, and nutrient transport:

  • CD46: Overexpressed on many epithelial cancers to protect against complement-mediated lysis; utilized by measles virus strains.
  • Integrins (e.g., \(\alpha_v\beta_3\), \(\alpha_v\beta_5\)): Upregulated during tumor angiogenesis and metastasis; serve as attachment factors for adenoviruses.
  • CAR (Coxsackievirus and Adenovirus Receptor): Frequently present on multiple carcinomas.
  • Nectin-4: Overexpressed in breast, bladder, and lung cancers; acts as an entry receptor for oncolytic measles and herpesviruses.

Engineered oncolytic viruses can also feature retargeted envelope glycoproteins or capsid modifications, directing viral entry specifically to tumor markers like EGFR or HER2.

Exploitation of Constitutive Oncogenic Signaling

Cancer cells harbor mutations in signaling pathways that promote continuous cell cycle progression and metabolic activity. Oncolytic viruses frequently capitalize on these active oncogenic pathways to drive their own replication:

Ras Pathway Activation

Activating mutations in the RAS gene family or hyperactivation of downstream pathways inhibit PKR autophosphorylation. In normal cells, PKR detects viral double-stranded RNA, phosphorylates eukaryotic initiation factor 2 alpha (eIF2\(\alpha\)), and halts translation. In Ras-transformed cells, this translational block is impaired, allowing oncolytic reoviruses and herpes simplex virus variants to synthesize viral proteins unhindered.

E2F and the Rb Pathway

Normal cells restrict entry into the S-phase via the retinoblastoma (Rb) protein, which represses the E2F transcription factor family. Tumors often display functional inactivation of Rb, liberating E2F. Genetically modified adenoviruses (such as those harboring mutations in the E1A region) cannot detach Rb on their own and are therefore replication-incompetent in normal cells. However, in malignant cells with pre-existing, constitutive E2F release, the virus replicates efficiently.

Genetic Engineering for Enhanced Selectivity

Beyond natural viral tropism, molecular engineering enhances selectivity and limits toxicity to non-transformed cells:

  • Gene Deletions: Viruses are often engineered with deletions in enzymes essential for replication in non-dividing cells. For instance, deletion of thymidine kinase (\(TK\)) in vaccinia virus or herpes simplex virus prevents the virus from replicating in normal quiescent cells. Malignant cells maintain high nucleotide pools via endogenous thymidine kinase expression, supplying the necessary substrates for viral genome replication.
  • Tumor-Specific Promoters: Essential viral genes can be placed under the transcriptional control of tumor-specific promoters, such as the prostate-specific antigen (PSA) promoter, alpha-fetoprotein (AFP) promoter, or the telomerase reverse transcriptase (TERT) promoter, preventing transcription in normal tissues.

Dual Action: Oncolysis and Antitumor Immunity

When selective replication culminates in cell lysis, oncolytic viruses do not merely clear malignant cells directly. Lysis triggers the release of viral progeny, tumor-associated antigens, danger-associated molecular patterns (DAMPs), and pathogen-associated molecular patterns (PAMPs) into the microenvironment. This converts "cold," immunologically silent tumors into "hot" environments, recruiting dendritic cells and cytotoxic T lymphocytes to sustain a systemic, adaptive immune attack against the remaining cancer cells.